면역조직화학(IHC) 시장 예측(-2030년) : 제품, 용도, 최종 사용자 및 지역별 세계 분석

According to Stratistics MRC, the Global Immunohistochemistry (IHC) Market is accounted for $2.50 billion in 2023 and is expected to reach $4.72 billion by 2030 growing at a CAGR of 9.50% during the forecast period. Immunohistochemistry (IHC) is a powerful technique used in the field of pathology and biomedical research to visualize the presence, localization, and abundance of specific proteins or antigens within tissue samples. It involves the use of antibodies that bind to target proteins in fixed tissue sections. Through a series of steps, including antigen retrieval, blocking, primary antibody incubation, and detection with a secondary antibody, IHC enables the identification of specific cellular components or markers.

According to the American Cancer Society 2023 Cancer Statistics, it is estimated that about 1.96 million new cases of cancer would be diagnosed in the United States in 2023, as compared to 1.89 million in 2021.

Market Dynamics:

Driver:

Increasing adoption of companion diagnostics

Companion diagnostics play a crucial role in personalized medicine by aiding in the selection of the most effective treatment for individual patients. Immunohistochemistry techniques are integral to companion diagnostics, enabling the identification of specific biomarkers and molecular targets within tissues. As precision medicine continues to gain traction, demand for companion diagnostics supported by immunohistochemistry techniques is growing, particularly in oncology and other areas requiring targeted therapies. This trend is expected to drive the expansion of the immunohistochemistry market as healthcare providers prioritize tailored treatment approaches based on patients' unique characteristics and molecular profiles.

Restraint:

Limited standardization

Limited standardization refers to the absence of universally accepted protocols and guidelines for sample preparation, staining techniques, and interpretation of results. This lack of standardization poses challenges for researchers and clinicians in achieving consistent and reproducible results across different laboratories and platforms. It leads to variations in staining intensity, specificity, and sensitivity, impacting the reliability and comparability of IHC data. Consequently, this constraint hinders the widespread adoption of IHC in clinical diagnostics and research applications, limiting its potential for guiding treatment decisions and advancing scientific understanding.

Opportunity:

Cancer research and diagnostics

IHC allows for the precise detection and localization of specific proteins within tissue samples, aiding in cancer diagnosis, prognosis, and treatment planning. With advancements in IHC technologies, researchers and clinicians can identify biomarkers associated with different cancer types, enabling personalized medicine approaches. This technique also facilitates the study of tumor microenvironments, contributing to a deeper understanding of cancer biology and potential therapeutic targets. As the demand for accurate cancer diagnosis and targeted therapies continues to grow, the IHC market stands poised to expand further, offering innovative solutions for improved patient care and outcomes.

Threat:

Price sensitivity

The price sensitivity threats are the risks posed by customers being highly responsive to changes in pricing. As IHC involves costly reagents, equipment, and expertise, pricing plays a critical role in purchasing decisions. In a price-sensitive market, customers may opt for cheaper alternatives or reduce their usage if prices rise. This can lead to decreased demand for IHC products and services, impacting revenues and profitability for companies operating in this sector. To mitigate this threat, companies must carefully balance pricing strategies with maintaining product quality and value propositions while also considering the competitive landscape and customer needs.

Covid-19 Impact:

With increased focus on understanding the virus and developing effective diagnostics and therapies, there has been a surge in demand for IHC tests for detecting viral antigens and assessing tissue damage caused by the virus. Additionally, disruptions in healthcare services and research activities during lockdowns have temporarily slowed down market growth. However, the pandemic has also accelerated technological advancements in IHC assays and automation, leading to greater efficiency and accuracy in testing processes. Overall, while the pandemic has posed challenges, it has also highlighted the importance of IHC in disease diagnosis and management, potentially driving long-term growth in the market.

The equipment segment is expected to be the largest during the forecast period

The equipment segment has been experiencing significant growth due to developments in technologies, which have led to the development of more efficient and user-friendly equipment. The increasing prevalence of cancer and chronic diseases has fueled demand for diagnostic techniques like IHC, thereby driving the market for related equipment. Moreover, rising healthcare expenditures globally have enabled healthcare facilities to invest in modern equipment for better patient care. Furthermore, the expanding application of immunohistochemistry techniques in research and drug development has further boosted demand for equipment in this segment.

The research application segment is expected to have the highest CAGR during the forecast period

The research application segment has experienced notable growth due to manufacturing of more sophisticated and sensitive IHC assays, catering to the complex requirements of research studies. The expanding scope of research in areas such as oncology, neuroscience, and immunology has fueled the demand for IHC techniques to analyze tissue samples for biomarker identification and characterization. Moreover, collaborations between academic institutions, research organizations, and biotechnology companies have facilitated the adoption of IHC in diverse research projects. Additionally, the rise in funding for biomedical research globally has further propelled the growth of this segment, enabling the exploration of novel applications and the validation of potential therapeutic targets using IHC.

Region with largest share:

North American region has witnessed substantial growth in the immunohistochemistry (IHC) because of the increasing prevalence of chronic diseases such as cancer, rising demand for personalized medicine, and advancements in diagnostic technologies. Favorable reimbursement policies, robust healthcare infrastructure, and a strong presence of key market players contribute to the expansion of the IHC market in North America. Furthermore, growing investments in research and development activities further propel market growth, with continuous efforts aimed at enhancing the efficiency and accuracy of diagnostic techniques.

Region with highest CAGR:

The Asia-Pacific region has experienced significant growth in the due to a growing number of geriatric population. The rising healthcare expenditure and infrastructure development in countries like China and India have contributed to market expansion. Additionally, advancements in technology, such as automation and digital pathology, have improved efficiency and accuracy in immunohistochemistry procedures, further driving market growth.

Key players in the market

Some of the key players in Immunohistochemistry (IHC) market include Abcam PLC, Agilent Technologies, Inc., Becton Dickinson and Company, Bio SB, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cell Signaling Technology, Inc., Danaher Corporation, F. Hoffmann-LA Roche AG, Merck KGaA, PerkinElmer, Inc., Takara Bio and Thermo Fisher Scientific Inc.

Key Developments:

In March 2024, Thermo Fisher Scientific Inc. announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrollment, is CorEvitas' 10th syndicated disease registry and addresses an unmet need for real-world evidence (RWE) related to the clinical and patient-reported outcomes of patients with GPP.

In February 2024, Danaher Corporation has launched a strategic collaboration with Cincinnati Children's Hospital Medical Center, with the goal of improving patient safety by addressing a leading cause of failure in clinical trials. As part of the Danaher Beacons program, the multi-year collaboration aims to improve liver organoid technology as a drug toxicity screening solution for safeguarding patients.

Products Covered:

• Antibodies
• Reagents
• Kits
• Equipment
• Other Products

Applications Covered:

• Diagnostic Application
• Research application
• Other Applications

End Users Covered:

• Forensic Laboratories
• Biopharma Companies
• Hospitals & Diagnostic Laboratories
• Academic & research Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Immunohistochemistry (IHC) Market, By Product

• 5.1 Introduction
• 5.2 Antibodies
  • 5.2.1 Primary antibodies
  • 5.2.2 Secondary antibodies
• 5.3 Reagents
  • 5.3.1 Diluents
  • 5.3.2 Proteolytic Enzymes
  • 5.3.3 Blocking Sera and Reagents
  • 5.3.4 Fixation Reagents
  • 5.3.5 Histological Stains
  • 5.3.6 Chromogenic Substrates
  • 5.3.7 Organic Solvents
  • 5.3.8 Stabilizers
  • 5.3.9 Mounting Solutions
  • 5.3.10 Antigen Retrieval Solutions
  • 5.3.11 Other Reagents
• 5.4 Kits
  • 5.4.1 IHC Kits for Animal tissue
  • 5.4.2 IHC Kits for Human tissue
• 5.5 Equipment
  • 5.5.1 Slide Scanners
  • 5.5.2 Automated Cover Slippers
  • 5.5.3 Microtomes
  • 5.5.4 Visualization Equipment
  • 5.5.5 Slide Labelers
  • 5.5.6 Tissue Microarrays
  • 5.5.7 Paraffin Dispensers
  • 5.5.8 Slide-staining Systems
  • 5.5.9 Tissue Processing Systems
  • 5.5.10 Other Equipment
• 5.6 Other Products

6 Global Immunohistochemistry (IHC) Market, By Application

• 6.1 Introduction
• 6.2 Diagnostic Application
  • 6.2.1 Cancer
  • 6.2.2 Infectious diseases
  • 6.2.3 Autoimmune diseases
  • 6.2.4 Nephrological diseases
  • 6.2.5 Neurological diseases
  • 6.2.6 Ophthalmic
  • 6.2.7 Dental Diseases
  • 6.2.8 Cardiovascular
  • 6.2.9 Dermatological
  • 6.2.10 Other Diagnostic Applications
• 6.3 Research application
  • 6.3.1 Drug development and Testing
  • 6.3.2 Developmental Biology
  • 6.3.3 Stem Cell Research
  • 6.3.4 Forensic applications
  • 6.3.5 Other Research Applications
• 6.4 Other Applications

7 Global Immunohistochemistry (IHC) Market, By End User

• 7.1 Introduction
• 7.2 Forensic Laboratories
• 7.3 Biopharma Companies
• 7.4 Hospitals & Diagnostic Laboratories
• 7.5 Academic & research Institutes
• 7.6 Other End Users

8 Global Immunohistochemistry (IHC) Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abcam PLC
• 10.2 Agilent Technologies, Inc.
• 10.3 Becton Dickinson and Company
• 10.4 Bio SB
• 10.5 Bio-Rad Laboratories, Inc.
• 10.6 Bio-Techne Corporation
• 10.7 Cell Signaling Technology, Inc.
• 10.8 Danaher Corporation
• 10.9 F. Hoffmann-LA Roche AG
• 10.10 Merck KGaA
• 10.11 PerkinElmer, Inc.
• 10.12 Takara Bio
• 10.13 Thermo Fisher Scientific Inc.